

PrISMA

Preparatory activities to support Implementation of quality and Safety of Medical ionising radiation Applications

Various technologies play a significant role in all aspects of cancer care, from early detection and diagnostics to therapy and palliative care. However, the increasing use of these technologies has raised concerns about the rising radiation exposure among the European population.

Aim

The aim of PrISMA is to explore the utility of, and pave the way for, a future SAMIRA Joint Action in the area of quality and safety of medical applications of ionising radiation.

Specific objectives

The **first** specific objective is to comprehensively map the relevant stakeholders in the Member States in the area of quality and safety in the medical use of ionising radiation and their respective areas of expertise. They will work together to define a proposed text setting out the objectives, scope and activities of the future SAMIRA Joint Action, which is the **second** specific objective of PrISMA.

Target groups

National authorities, healthcare organisations, professional bodies, research institutions, and patient organisations.

Expected Results and Benefits to Patients and Society

A successful implementation of PrISMA and the future Joint Action will lead to a sustainable, high-quality, and safe, diagnostic and therapeutic use of medical ionising radiation for citizens in Europe.

EC contribution: € 1.000.000 Co-funding by EU
Duration: Starting May 2024 – Ending October 2025

Contact us via email if you have any questions:
SAMIRA@rivm.nl

For more information visit:
www.rivm.nl/en/samira-prisma



PrISMA consortium members

- The Netherlands, National Institute for Public Health and the Environment (RIVM), Coordinator;
- Finland, Radiation and Nuclear Safety Authority (STUK);
- Finland, Ministry of Social Affairs and Health (MSAH);
- Sweden, Medical Products Agency (MPA);
- Sweden, Radiation Safety Authority (SSM);
- Norway, Norwegian Radiation and Nuclear Safety Authority (DSA);
- Norway, Norwegian Directorate of Health (HDIR);
- Spain, Catalan Institute of Oncology (ICO);
- Spain, Agencia Española de Medicamentos y Productos Sanitarios (AEMPS);
- Lithuania, Hospital of Lithuanian University of Health Sciences Kauno klinikos (LSMULKK);
- Italy, Istituto Superiore di Sanità (ISS);
- Italy, Policlinico Universitario Agostino Gemelli IRCCS (FPG-UCSC);
- Hungary, National Center for Public Health and Pharmacy (NCPHP);
- Denmark, Danish Health Authority (Sundhedsstyrelsen, SST);
- Croatia, Klinicka Bolnica Dubrava – Dubrava University Hospital (DUH);
- Croatia, Croatian Medical Physics Association (CROMPA);
- Portugal, Directorate General of Health (DGS);
- Ireland, Health Information and Quality Authority (HIQA).



Co-funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union of the Health and Digital Executive Agency (HaDEA). Neither the European Union nor the granting authority can be held responsible for them.